Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SKI II (SphK-I2) is a highly selective and non-ATP-competitive S1P receptor inhibitor (IC50: 0.5 μM) while exhibiting no inhibitory action on other kinases including PKCα, PI3K, and ERK2.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
5 mg | 在庫あり | ¥ 9,000 | |||
10 mg | 在庫あり | ¥ 13,000 | |||
25 mg | 在庫あり | ¥ 25,000 | |||
50 mg | 在庫あり | ¥ 43,000 | |||
100 mg | 在庫あり | ¥ 75,000 | |||
200 mg | 在庫あり | ¥ 135,500 | |||
500 mg | 在庫あり | ¥ 216,500 |
説明 | SKI II (SphK-I2) is a highly selective and non-ATP-competitive S1P receptor inhibitor (IC50: 0.5 μM) while exhibiting no inhibitory action on other kinases including PKCα, PI3K, and ERK2. |
ターゲット&IC50 | SPHK:0.5 μM |
In vitro | SKI II (50 mg/kg, i.p.) improves bronchial smooth muscle hyperreactivity induced by antigens in mice by inhibiting the production of endogenous sphingosine-1-phosphate. In a homologous Balb/c mouse model with JC mammary carcinoma cells, SKI II (50 mg/kg, i.p./p.o.) significantly reduces tumor growth without evident toxicity or weight loss compared to the control group. |
In vivo | Consistent with its role in reducing S1P levels, SKI II induces apoptosis in T24 cells. In JC cells, SKI II decreases S1P formation in a concentration-dependent manner (IC50: 12 μM). Additionally, in the breast cancer cell line MDA-MB-231, SKI II significantly inhibits endogenous SK activity. Among various human cancer cell lines, including T-24, MCF-7, MCF-7/VP, and NCI/ADR, SKI II demonstrates notable antiproliferative effects (IC50: 4.6/1.2/0.9/1.3 μM). Furthermore, SKI II reverses the cisplatin resistance in SGC7901/DDP by downregulating P-gp expression and inducing apoptosis through the downregulation of SPHK1. |
キナーゼ試験 | SK Assay: A medium-throughput assay suitable for screening for inhibitors of recombinant human SK has been established. Briefly, 5 μg of purified GST-SK fusion protein are combined with 12 nM sphingosine, which contains a 100-fold dilution of [3-3H]sphingosine (20 Ci/mmol), 1 mM ATP, 1 mM magnesium chloride, and 200 μL of assay buffer [20 mM Tris HCl (pH 7.4), 20% glycerol, 1 mM beta-mercaptoethanol, 1 mM EDTA, 20 mM zinc chloride, 1 mM sodium orthovanadate, 15 mM sodium fluoride, and 0.5 mM 4-deoxypyridoxine]. Assays are run for 30 min at 25°C with shaking and contains either 1% DMSO or 5 g/mL test compound, which corresponds to concentrations of 10–25 μM. The reactions are terminated with 50 μL of concentrated ammonium hydroxide, followed by extraction of the assay mixture with chloroform:methanol (2:1). The aqueous portion is transferred to scintillation vials and radioactivity is quantified as a measure of [3H]]S1P formation using a Beckman LS 3801 Scintillation Counter. The intra-assay coefficient of variation is ~10%, whereas interassay variation is ~20%. |
細胞研究 | T24, MCF-7, MCF-7/VP, and NCI/ADR cells are plated into 96-well tissue culture plates at ~15% confluency. After 24 hours, cells are treated with various concentrations of inhibitors. After an additional 48 hours, cell survival is assayed using the sulforhodamine B assay.(Only for Reference) |
別名 | SphK-I2 |
分子量 | 302.78 |
分子式 | C15H11ClN2OS |
CAS No. | 312636-16-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30.3 mg/mL (100 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SKI II 312636-16-1 Apoptosis Cytoskeletal Signaling GPCR/G Protein Stem Cells S1P Receptor Wnt/beta-catenin Sphingosine kinase SphK-I2 SphK Wnt Inhibitor inhibit inhibitor